PL424452A1 - Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu - Google Patents

Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu

Info

Publication number
PL424452A1
PL424452A1 PL424452A PL42445218A PL424452A1 PL 424452 A1 PL424452 A1 PL 424452A1 PL 424452 A PL424452 A PL 424452A PL 42445218 A PL42445218 A PL 42445218A PL 424452 A1 PL424452 A1 PL 424452A1
Authority
PL
Poland
Prior art keywords
endopeptidase
hsep
nep
prevention
treatment
Prior art date
Application number
PL424452A
Other languages
English (en)
Inventor
Christopher Turski
Original Assignee
Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością filed Critical Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL424452A priority Critical patent/PL424452A1/pl
Priority to US16/963,234 priority patent/US20210046097A1/en
Priority to PCT/PL2019/000012 priority patent/WO2019151882A1/en
Priority to TW108103768A priority patent/TWI762760B/zh
Priority to EP19747023.0A priority patent/EP3746106B1/en
Priority to RS20240670A priority patent/RS65651B1/sr
Priority to PL19747023.0T priority patent/PL3746106T3/pl
Priority to HRP20240728TT priority patent/HRP20240728T1/hr
Priority to MX2020007989A priority patent/MX2020007989A/es
Priority to CA3088966A priority patent/CA3088966A1/en
Priority to RU2020125048A priority patent/RU2758771C1/ru
Priority to CN201980011177.2A priority patent/CN111757750A/zh
Priority to KR1020207025030A priority patent/KR20200116145A/ko
Publication of PL424452A1 publication Critical patent/PL424452A1/pl
Priority to ZA2019/05959A priority patent/ZA201905959B/en
Priority to IL275984A priority patent/IL275984A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Zgłoszenie dotyczy nowego zastosowania pochodnych benzazepiny, benzoksazepiny, kwasu benzotiazepino-N-octowego oraz fosfono-podstawionego benzazepinonu o aktywności hamującej obojętną endopeptydazę (NEP) i/lub ludzką rozpuszczalną endopeptydazę (hSEP). Związki te stosuje się do wytwarzania kompozycji farmaceutycznych do profilaktyki i leczenia chorób oczu.
PL424452A 2018-01-31 2018-01-31 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu PL424452A1 (pl)

Priority Applications (15)

Application Number Priority Date Filing Date Title
PL424452A PL424452A1 (pl) 2018-01-31 2018-01-31 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
HRP20240728TT HRP20240728T1 (hr) 2018-01-31 2019-01-31 Inhibitori neutralne endopeptidaze (nep) i humane topljive endopeptidaze (hsep) za profilaksu i liječenje bolesti oka
MX2020007989A MX2020007989A (es) 2018-01-31 2019-01-31 Inhibidores de endopeptidasa neutra (nep) y endopeptidasa soluble humana (hsep) para profilaxis y tratamiento de enfermedades oftalmologicas.
TW108103768A TWI762760B (zh) 2018-01-31 2019-01-31 用於預防或治療眼部疾病的中性肽鏈內切酶(NEP)及人類可溶性肽鏈內切酶(hSEP)之抑制劑
EP19747023.0A EP3746106B1 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of eye diseases
RS20240670A RS65651B1 (sr) 2018-01-31 2019-01-31 Inhibitori neutralne endopeptidaze (nep) i humane rastvorive endopeptidaze (hsep) za profilaksu i lečenje očnih bolesti
PL19747023.0T PL3746106T3 (pl) 2018-01-31 2019-01-31 Inhibitory obojętnej endopeptydazy (nep) i ludzkiej rozpuszczalnej endopeptydazy (hsep) do profilaktyki i leczenia chorób oczu
US16/963,234 US20210046097A1 (en) 2018-01-31 2019-01-31 NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS FOR PROPHYLAXIS AND TREATMENT OF EYE DISEASES
PCT/PL2019/000012 WO2019151882A1 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of eye diseases
CA3088966A CA3088966A1 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of eye diseases
RU2020125048A RU2758771C1 (ru) 2018-01-31 2019-01-31 ИНГИБИТОРЫ НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ (НЭП) И РАСТВОРИМОЙ ЭНДОПЕПТИДАЗЫ ЧЕЛОВЕКА (РЭПч) ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГЛАЗНЫХ БОЛЕЗНЕЙ
CN201980011177.2A CN111757750A (zh) 2018-01-31 2019-01-31 用于预防和治疗眼病的中性内肽酶(nep)及人类可溶性内肽酶(hsep)的抑制剂
KR1020207025030A KR20200116145A (ko) 2018-01-31 2019-01-31 안 질환의 예방 및 치료를 위한 중성 엔도펩티다제 (NEP) 및 사람 용해성 엔도펩티다제 (hSEP) 억제제
ZA2019/05959A ZA201905959B (en) 2018-01-31 2019-09-10 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of eye diseases
IL275984A IL275984A (en) 2018-01-31 2020-07-12 Human neutral endopeptidase and soluble endopeptidase inhibitors for the prevention and treatment of eye diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL424452A PL424452A1 (pl) 2018-01-31 2018-01-31 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu

Publications (1)

Publication Number Publication Date
PL424452A1 true PL424452A1 (pl) 2019-08-12

Family

ID=67478423

Family Applications (2)

Application Number Title Priority Date Filing Date
PL424452A PL424452A1 (pl) 2018-01-31 2018-01-31 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
PL19747023.0T PL3746106T3 (pl) 2018-01-31 2019-01-31 Inhibitory obojętnej endopeptydazy (nep) i ludzkiej rozpuszczalnej endopeptydazy (hsep) do profilaktyki i leczenia chorób oczu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19747023.0T PL3746106T3 (pl) 2018-01-31 2019-01-31 Inhibitory obojętnej endopeptydazy (nep) i ludzkiej rozpuszczalnej endopeptydazy (hsep) do profilaktyki i leczenia chorób oczu

Country Status (14)

Country Link
US (1) US20210046097A1 (pl)
EP (1) EP3746106B1 (pl)
KR (1) KR20200116145A (pl)
CN (1) CN111757750A (pl)
CA (1) CA3088966A1 (pl)
HR (1) HRP20240728T1 (pl)
IL (1) IL275984A (pl)
MX (1) MX2020007989A (pl)
PL (2) PL424452A1 (pl)
RS (1) RS65651B1 (pl)
RU (1) RU2758771C1 (pl)
TW (1) TWI762760B (pl)
WO (1) WO2019151882A1 (pl)
ZA (1) ZA201905959B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102647920B1 (ko) 2021-10-13 2024-03-13 영남대학교 산학협력단 거짓비늘 녹내장 바이오 마커
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191436B1 (pl) * 1997-11-12 2006-05-31 Solvay Pharm Gmbh Podstawione ugrupowaniem kwasu fosfonowego pochodne benzazepinonu zawierające przy atomie N-ugrupowanie kwasu octowego, sposób ich wytwarzania i środki farmaceutyczne zawierające te związki
EP1706121A1 (en) * 2004-01-12 2006-10-04 Solvay Pharmaceuticals B.V. Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders
WO2007056497A1 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE400277T1 (de) * 1998-03-05 2008-07-15 Senju Pharma Co Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
AR039352A1 (es) * 2001-05-18 2005-02-16 Solvay Pharm Gmbh Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5.
RU2303041C2 (ru) 2002-01-16 2007-07-20 Солвей Фармасьютикалс Б.В. Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений
AR038681A1 (es) 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2004062692A1 (en) 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
CL2004000545A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
WO2005039639A2 (en) * 2003-10-10 2005-05-06 Solvay Pharmaceuticals Gmbh Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
US7232813B2 (en) * 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
DK2470191T3 (da) * 2009-08-24 2014-07-07 Stealth Peptides Int Inc Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191436B1 (pl) * 1997-11-12 2006-05-31 Solvay Pharm Gmbh Podstawione ugrupowaniem kwasu fosfonowego pochodne benzazepinonu zawierające przy atomie N-ugrupowanie kwasu octowego, sposób ich wytwarzania i środki farmaceutyczne zawierające te związki
EP1706121A1 (en) * 2004-01-12 2006-10-04 Solvay Pharmaceuticals B.V. Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders
WO2007056497A1 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators

Also Published As

Publication number Publication date
IL275984A (en) 2020-08-31
ZA201905959B (en) 2021-07-28
TWI762760B (zh) 2022-05-01
MX2020007989A (es) 2020-09-09
EP3746106B1 (en) 2024-03-27
HRP20240728T1 (hr) 2024-08-30
EP3746106A4 (en) 2021-11-03
WO2019151882A4 (en) 2019-09-26
US20210046097A1 (en) 2021-02-18
CN111757750A (zh) 2020-10-09
EP3746106C0 (en) 2024-03-27
RS65651B1 (sr) 2024-07-31
PL3746106T3 (pl) 2024-06-24
WO2019151882A1 (en) 2019-08-08
TW201934536A (zh) 2019-09-01
CA3088966A1 (en) 2019-08-08
KR20200116145A (ko) 2020-10-08
EP3746106A1 (en) 2020-12-09
RU2758771C1 (ru) 2021-11-01

Similar Documents

Publication Publication Date Title
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
CL2015003442A1 (es) Derivados heterociclicos
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
PH12020500257A1 (en) Quinoline derivatives for treating infections with helminths
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
MX2013010795A (es) 1,3 oxazinas como inhibidores de beta-secretasa 1 (bace 1) y/o la beta-secretasa 2 (beta 2).
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
EA201391752A1 (ru) Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2
MD3532459T2 (ro) Inhibitori ai LSD1 și utilizările medicale ale acestora
MX2019012803A (es) Nuevos derivados de pirazol biciclicos.
EA200901484A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
PH12020551891A1 (en) New quinoline derivatives
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
EA201891610A1 (ru) Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
PL424452A1 (pl) Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
EA201991490A1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
CO2017007691A2 (es) Inhibidores de la β-secretasa derivados de la 5-amino-3-(5-(3-isoxazol-5-il)-3-(fluorometil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina o 5-amino-3-(5-(1h-1,2,3-triazol-4-il)-2-fluorofenil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina composiciones que los comprenden y métodos de elaboración
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
WO2012102560A3 (ko) 신규한 4-ｏ-메틸호노키올 유도체 및 이를 유효성분으로 포함하는 염증질환 치료용 조성물